In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
- 1 September 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (9) , 1580-1587
- https://doi.org/10.1128/aac.33.9.1580
Abstract
The penem BRL 42715, C6-(N1-methyl-1,2,3-triazolylmethylene)penem, is a potent inhibitor of a broad range of bacterial beta-lactamases, including the plasmid-mediated TEM, SHV, OXA, and staphylococcal enzymes, as well as the chromosomally mediated enzymes of Bacteroides, Enterobacter, Citrobacter, Serratia, Morganella, Escherichia, Klebsiella, and Proteus species. The concentration of BRL 42715 needed to reduce the initial rate of hydrolysis of most beta-lactamase enzymes by 50% was less than 0.01 micrograms/ml, which was 10- to 100-fold lower than for other beta-lactamase inhibitors. These potent inhibitory activities were reflected in the low concentrations of BRL 42715 needed to potentiate the antibacterial activity of beta-lactamase-susceptible beta-lactams. Concentrations of 0.25 micrograms/ml or less considerably enhanced the activity of amoxicillin against many beta-lactamase-producing strains. The MIC50 (MIC for 50% of strains tested) of amoxicillin for 412 beta-lactamase-producing members of the family Enterobacteriaceae fell from greater than 128 to 2 micrograms/ml in the presence of 1 microgram of BRL 42715 per ml, whereas 5 micrograms of clavulanic acid per ml brought the MIC50 down to 8 micrograms/ml. Among these 412 strains were 73 Citrobacter and Enterobacter strains, and 1 microgram of BRL 42715 per ml reduced the MIC50 of amoxicillin from greater than 128 to 2 micrograms/ml for the 48 cefotaxime-susceptible strains and from greater than 128 to 8 micrograms/ml for the 25 cefotaxime-resistant strains.This publication has 20 references indexed in Scilit:
- Characterization of beta-lactamasesAntimicrobial Agents and Chemotherapy, 1989
- Chromosomal -lactamase expression and antibiotic resistance in Enterobacter cloacaeJournal of Medical Microbiology, 1988
- Chromosomal Cephalosporinases Responsible for Multiple Resistance to Newer β-Lactam AntibioticsAnnual Review of Microbiology, 1987
- Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporinsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Structure-Activity Relationships Amongst β-Lactamase InhibitorsJournal of Enzyme Inhibition, 1986
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- Development of resistance to cephalosporins in clinical strains of Citrobacter sppAntimicrobial Agents and Chemotherapy, 1984
- In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillinJournal of Antimicrobial Chemotherapy, 1980
- Plasmid-mediated β-lactamases of Gram-negative bacteria: properties and distributionJournal of Antimicrobial Chemotherapy, 1979
- CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological CharacterizationAntimicrobial Agents and Chemotherapy, 1978